Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study

BACKGROUND: Conventional criteria for tumor progression may not fully reflect the clinical benefit of immunotherapy or appropriately guide treatment decisions. The phase II IMvigor210 study demonstrated the efficacy and safety of atezolizumab, a programmed death-ligand 1-directed antibody, in patien...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Oncol
Main Authors: Necchi, A, Joseph, R W, Loriot, Y, Hoffman-Censits, J, Perez-Gracia, J L, Petrylak, D P, Derleth, C L, Tayama, D, Zhu, Q, Ding, B, Kaiser, C, Rosenberg, J E
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5834063/
https://ncbi.nlm.nih.gov/pubmed/28950298
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdx518
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados